BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
We like the continued outperformance in Kewal Kiran Clothing Ltd.’s Killer franchise and the visibly higher aggression towards retail expansion in this format.
Even though meaningful improvement (18% YoY versus 9% YoY in Q2 FY23) in realisation is encouraging (benefits of price hikes and mix improvement), underperformance in volumes (down 2% YoY versus 18% in Q2 FY23) is a matter of concern.
We understand that the price hikes executed by Kewal Kiran (especially in jeans, which account for ~50% of sales) have been competitive (lower than the top competition, e.g. Levis, Pepe, etc.).
As a result, operating margins were impacted (gross margin remains below pre-Covid levels). However, we believe this situation will also enable Kewal Kiran to gain market share from the competition.
Expansion of exclusive brand outlets continues to be aggressive (~28-30% growth) primarily led by the Killer brand. Operating margins remained healthy during the quarter.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
![](https://images.assettype.com/bloombergquint/2024-08-22/xhk3qgch/GS2cZcmXgAAVGss.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
ICICI Lombard Focuses On Retail With Innovative Health Products
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2024-08-06/qbstf2gv/dillon-wanner-LxAM5DiHWCo-unsplash.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Surat's Kiran Gems Announces 10-Day Vacation For Employees Amid Low Diamond Demand
![timelogo](/images/amp-time.png)
'Would Like GST Exemption On All Cancer Drugs' Kiran Mazumdar Shaw | NDTV Profit
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2024-07/3d4497b9-a0c3-4938-a708-d98cfe90f63e/o4wiVL7g_400x400.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Budget 2024: Biocon's Kiran Mazumdar-Shaw Positive On Budget, Stresses GST Rationalisation
![timelogo](/images/amp-time.png)